Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab, John RandolphfiledCriticalAbbott Lab
Publication of GT201100074ApublicationCriticalpatent/GT201100074A/en
COMPUESTOS EFICACES PARA INHIBIR LA REPLICACIÓN DEL VIRUS DE LA HEPATITIS C, HCV. ESTA INVENCIÓN TAMBIÉN SE RELACIONA CON PROCESOS DE ELABORACIÓN DE TALES COMPUESTOS, CON COMPOSICIONES QUE COMPRENDEN A DICHOS COMPUESTOS Y CON MÉTODOS DE USO DE DICHOS COMPUESTOS PARA TRATAR UNA INFECCIÓN POR HCV.EFFECTIVE COMPOUNDS TO INHIBIT THE REPLICATION OF THE VIRUS OF HEPATITIS C, HCV. THIS INVENTION IS ALSO RELATED TO PROCESSES OF ELABORATION OF SUCH COMPOUNDS, WITH COMPOSITIONS THAT INCLUDE SUCH COMPOUNDS AND WITH METHODS OF USE OF SUCH COMPOUNDS TO TREAT AN INFECTION BY HCV.
Compounds derived from macrocyclic prolines, inhibitors of hepatitis C virus serine proteases (vhc); pharmaceutical composition that includes them; and its use to treat a viral infection such as hepatitis C virus (vhc) infection.
Compounds derived from biphenyl-pyrrolidinyl-imidazole; pharmaceutical composition comprising them; its use in the treatment of an hcv viral infection.
Benzimidazole-imidazole derivative compounds, hepatitis c virus (hcv) inhibitors; pharmaceutical composition comprising them; pharmaceutical combination; use in the prevention or treatment of hcv infection.
Compounds derived from thiophene-2-carboxylic acid, flaviviridae virus inhibitors; pharmaceutical composition that includes them; and its use for the treatment of a viral infection by flaviviridae.
Compounds derived from condensed heterocycles, hepatitis c virus inhibitors; pharmaceutical composition that contains them; and its use for the treatment of hepatitis c virus infection.
Compounds derived from nucleosides, hepatitis c virus inhibitors; preparation procedure; pharmaceutical composition that includes them; and pharmaceutical combination.
Compounds derived from benzofuran and its salts, as hepatitis c virus inhibitors; pharmaceutical composition that includes them; and its use for the treatment or prevention of an infection with the hepatitis c virus or a disease associated with said infection.